Investors may believe Shanghai Kaibao Pharmaceutical's stron...
Investors may believe Shanghai Kaibao Pharmaceutical's strong earnings growth could underperform the broader market, causing its low P/E ratio. If recent medium-term earnings trends persist, a significant share price rise seems unlikely.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000002432de6a84ad8c.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment